Oncolytic Therapy for Melanoma: An APP-Focused Education Curriculum
Released On
May 13, 2025
Expires On
May 12, 2026
Media Type
Internet
Completion Time
90 minutes
Specialty
Dermatology, Education, Hematology-Oncology, Pathology, Pharmacy, Surgery
Topic(s)
Skin Cancer, Melanoma
This activity is jointly provided by Partners for Advancing Clinical Education; Terranova Medica, LLC; Advanced Practitioner Society for Hematology and Oncology (APSHO); and the Integrita Healthcare Education Foundation.
This activity is supported by an independent educational grant from Replimune.
Credit Available
- Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)™
- Nurses — 1.5 contact hours
- Pharmacists — 1.5 Contact Hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is intended for oncology care providers (including physicians, advanced practice providers, nurses, pharmacists, and other healthcare providers) who care for patients with melanoma skin cancer.
Program Overview
Oncolytic therapy was first introduced in the field of oncology a decade ago. Recently, advancements have been made in oncolytic therapy, with the promise of potentially transforming the melanoma treatment landscape. In anticipation of an expanded role for oncolytic therapy, providers need updates on the mechanism of action, efficacy, safety, and practical aspects of each regimen. Advanced practice providers often spearhead the adoption of technologies such as intralesional injections in health systems. Therefore, they need up-to-date education about oncolytic therapies, opportunities to develop competency in intralesional injections, as well as support for credentialing. This curriculum, which carries the Advanced Practitioner Society for Hematology and Oncology (APSHO) Seal of Acceptance, contains didactic content on oncolytic therapies, instructional videos on techniques for intralesional injections, supportive strategies for credentialing, as well as a future opportunity for hands-on training for intralesional injections at JADPRO Live. We trust that you will find this content helpful in the adoption of an expanded role for oncolytic therapies in melanoma.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the mechanism of action of oncolytic therapy
- Compare and contrast the structure and function of different oncolytic therapies
- Discuss the data for different oncolytic therapies in melanoma
- Define communication strategies for patients receiving oncolytic therapies
- Identify oncolytic therapy injection techniques for different types of lesions
- List steps that can be taken toward credentialing for oncolytic therapies
Faculty
Lisa Kottschade, APRN, MSN, CNP, FAPO
Chair
Nurse Practitioner
Associate Professor of Oncology
Mayo Clinic College of Medicine
Rochester, Minnesota
Additional Faculty
Suzanne McGettigan, MSN CRNP AOCN®
Oncology Nurse Practitioner
Senior Clinical Manager
Division of Hematology-Oncology
Abramson Cancer Center
University of Pennsylvania Health System
Philadelphia, Pennsylvania
Margaret "Meg" Leddy, PA-C, MMSc
Physician Assistant – Oncology
Duke Cancer Center
Durham, North Carolina
Accreditation Statement
APSHO Seal of Acceptance
APSHO is a national, non-profit, professional society with its mission to improve the quality of care for patients with cancer by supporting critical issues in educational, clinical, and professional development for advanced practitioners in hematology and oncology. APSHO believes that high-quality, cost-effective oncology patient care is best delivered through collaborative practice models that optimize the role of advanced practitioners. The APSHO Seal of Acceptance indicates that an entity bearing the seal is consistent with standards of practice and quality care while recognizing the role of the oncology/hematology advanced practitioner.
Programs and materials submitted for the APSHO Seal of Acceptance are evaluated by APSHO advanced practitioner clinical experts (that includes pharmacists, nurse practitioners, and physician assistants). They must meet all review criteria for approval, including consistency with standards of practice and quality care.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners); Terranova Medica, LLC; Advanced Practitioner Society for Hematology and Oncology (APSHO); and Integrita Healthcare Education Foundation. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation
Physician Continuing Medical Education
Partners designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Designated for 1.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Continuing Pharmacy Education
Partners designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number – JA4008073-9999-25-144-H01-P
Type of Activity: Knowledge
Disclosures of Conflicts of Interest
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Faculty Disclosures
- Lisa Kottschade, APRN, MSN, CNP, FAPO
- Consultancy/Advisory Board: Immunocore
- Advisor: Replimune
- Suzanne McGettigan, MSN CRNP AOCN®
- Speakers Bureau/Honoraria for non-CME: Bristol Myers Squibb, Regeneron, Pfizer, Merck
- Consultancy/Advisory Board: Bristol Myers Squibb, Regeneron, Pfizer, Merck
- Margaret "Meg" Leddy, PA-C, MMSc
- Consultancy/Advisory Board: Replimune
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. During the accreditation period, participants must read the learning objectives and faculty disclosures and study the educational activity.
Participation in this self-study activity should be completed in approximately 1.5 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from 5/13/2025 through 5/12/2026:
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity quiz(zes)
- Complete the activity evaluation
You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate.
For Pharmacists: Upon successfully completing the post-assessment, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.
Certificates will be immediately available to the participant.
Course Viewing Requirements
To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred).
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
For further information, contact Tom Davis by telephone (877-276-4523), or by email [email protected].